# Tirzepatide: Frequently Asked Questions

> Tirzepatide frequently asked questions — mechanism, weight loss, side effects, half-life, FDA approval, and how it compares to semaglutide. Answers drawn from the published literature.

## How does tirzepatide work for weight loss?

Tirzepatide activates two gut hormone receptors — GIP and GLP-1 — simultaneously, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Engaging both receptors with a single molecule produced greater body-weight reduction than a selective GLP-1 agonist alone in preclinical studies [1]. The phase 3 SURMOUNT-1 trial in 2,539 adults without diabetes documented mean weight loss of -20.9% at 15 mg over 72 weeks [4].

## How much weight can you lose on tirzepatide?

In the SURMOUNT-1 phase 3 trial (72 weeks, n=2,539, adults without type 2 diabetes), mean weight changes were -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo [4]. At 15 mg, 50% of participants achieved at least 20% weight loss, and 91% achieved at least 5%. In SURMOUNT-5, a direct head-to-head against semaglutide, the mean loss was -20.2% with tirzepatide versus -13.7% with semaglutide [5].

## How long does it take for tirzepatide to work?

In SURPASS-2, HbA1c reductions were measurable at week 10 and continued to improve through week 40 [3]. In SURMOUNT-1, meaningful weight reductions were observed within the first 4-8 weeks of escalation and continued through the plateau at approximately week 60-72 [11]. The rate of weight loss is greatest during the first 6-12 months; most participants reach a weight plateau by week 72 [11].

## Why am I not losing weight on tirzepatide?

Weight loss plateaus are a normal and expected part of the treatment arc, reported by most participants by week 72 in SURMOUNT-1 and SURMOUNT-4 [11]. Higher doses, younger age, and female sex are associated with a longer time to plateau [11]. Factors that may attenuate weight loss include insufficient caloric adjustment, sleep disruption, stress, or metabolic adaptation. A plateau after initial weight loss does not indicate treatment failure.

## Does tirzepatide burn fat or just suppress appetite?

Both effects are documented. Appetite suppression — mediated through GLP-1R and GIP receptor signalling on central nervous system circuits — reduces food intake. The drug also alters energy partitioning: body-composition substudies found approximately 75% of weight lost was fat mass and 25% lean mass [36]. Whether GIP receptor activation produces direct metabolic effects on adipose tissue, distinct from the appetite reduction, remains an active area of research.

## What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and the GLP-1 receptor (glucagon-like peptide-1 receptor) with a single molecule. It is the first approved dual incretin receptor agonist. It is FDA-approved for type 2 diabetes (May 2022) and for chronic weight management in adults with obesity (November 2023). Given as a once-weekly subcutaneous injection, it has an approximately five-day half-life [1, 7].

## How does tirzepatide work?

Tirzepatide activates the GIP receptor and the GLP-1 receptor simultaneously. GIP and GLP-1 are incretin hormones — gut-derived peptides released after meals that stimulate glucose-dependent insulin secretion and contribute to satiety signalling. Engaging both receptors with one molecule enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, producing larger glycemic and weight effects in trials than selective GLP-1 agonism alone [1, 2].

## What does tirzepatide do in the body?

At the receptor level, tirzepatide activates both GIPR and GLP-1R, producing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced caloric intake via central appetite regulation [1, 2]. In the SURPASS trials it lowered HbA1c (a blood-sugar marker) by up to 2.30 percentage points in type 2 diabetes [3]. In the SURMOUNT trials it reduced body weight by up to -20.9% in adults with obesity [4]. Cardiometabolic benefits — reduced blood pressure, improved lipids, reduced insulin resistance — tracked proportionally with the degree of weight loss [15].

## What is tirzepatide used for?

Tirzepatide has three FDA-approved indications: type 2 diabetes mellitus (as adjunct to diet and exercise, approved May 2022); chronic weight management in adults with obesity or with overweight plus at least one weight-related comorbidity (approved November 2023); and moderate-to-severe obstructive sleep apnea in adults with obesity (approved after SURMOUNT-OSA results) [12, 7, 17]. Clinical trials have also investigated it in heart failure with preserved ejection fraction (SUMMIT) [13] and metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH) [14].

## Is tirzepatide a GLP-1?

Tirzepatide activates the GLP-1 receptor, but it is not a selective GLP-1 receptor agonist — it is a dual GIP and GLP-1 receptor agonist. It activates the GIP receptor more fully than the GLP-1 receptor (the "imbalanced" dual agonism characterized by Willard FS et al. 2020) [2]. This distinguishes it from selective GLP-1 receptor agonists, which act only at the GLP-1 receptor. The dual mechanism is what produced greater weight reduction than semaglutide in SURMOUNT-5 [5].

## What are the side effects of tirzepatide?

The most common side effects across trials are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. A systematic review and meta-analysis of nine randomized trials found the composite gallbladder-or-biliary-disease risk significantly increased versus controls (relative risk 1.97, 95% CI 1.14-3.42) [25]. Injection site reactions are the second most frequently reported category in post-marketing data. Hair loss (telogen effluvium) has been reported in a subset of users [39].

## What are the bad side effects of tirzepatide?

The most clinically significant adverse effects are: the gastrointestinal burden during dose escalation (which drives most treatment discontinuations) [21, 22]; the gallbladder and biliary disease signal (relative risk approximately 1.97 versus controls in a meta-analysis of nine trials) [25]; hypoglycemia when combined with insulin or sulfonylureas [26]; and lean-mass loss accompanying fat loss (approximately 25% of weight lost is lean mass in body-composition substudies) [36]. The boxed thyroid C-cell warning is based on rodent data and has not been confirmed in humans [26].

## Does tirzepatide cause diarrhea?

Diarrhea is among the most commonly reported gastrointestinal adverse events in both clinical trials and post-market safety data. A bibliometric pharmacovigilance analysis of FAERS data found gastrointestinal events were the dominant safety signal in real-world reporting [23]. In SURMOUNT-1, diarrhea was reported in approximately 17-25% of participants at the higher doses, predominantly during dose escalation and easing thereafter [4]. An alternating pattern of constipation and diarrhea is frequently reported in patient community accounts.

## What is the difference between semaglutide and tirzepatide?

Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide activates both the GIP receptor and the GLP-1 receptor. In SURMOUNT-5 (72-week head-to-head in adults without diabetes), tirzepatide at maximum tolerated dose produced -20.2% weight loss versus -13.7% with semaglutide at maximum tolerated dose [5]. In SURPASS-2 (type 2 diabetes), tirzepatide produced greater HbA1c and weight reduction than semaglutide 1 mg at all three tested doses [3]. Both drugs are once-weekly subcutaneous injections.

## Is tirzepatide better than semaglutide?

In head-to-head trials, tirzepatide outperformed semaglutide on weight reduction and glycemic control in both type 2 diabetes (SURPASS-2) and obesity without diabetes (SURMOUNT-5). SURMOUNT-5 found -20.2% versus -13.7% body-weight reduction (P<0.001) [5]. The tolerability picture is mixed: a meta-analysis of three head-to-head trials versus dulaglutide (a GLP-1 agonist in the same class) found discontinuation due to adverse events was approximately 32% higher with tirzepatide, driven by gastrointestinal effects [6]. Whether tirzepatide is the better choice for a specific person is a clinical question not addressable by this editorial digest.

## How long does tirzepatide stay in your system?

Tirzepatide has an elimination half-life of approximately five days, consistent with its fatty-acid modification that confers albumin binding and resistance to enzymatic degradation [1]. At once-weekly dosing, steady-state plasma concentrations are reached within two to three weeks. After the last dose, the drug clears to negligible concentrations over approximately 25-30 days (five half-lives). Weight begins to return after cessation of treatment, reflecting the drug's mechanism-dependent effect on appetite [18].

## What is the half-life of tirzepatide?

The elimination half-life is approximately five days (roughly 120 hours), established in phase 1 pharmacokinetic studies and confirmed across the clinical programme [1]. This half-life supports once-weekly dosing with stable plasma concentrations. It is produced by the fatty-diacid arm of the molecule — a C20 fatty diacid attached via a glutamic acid linker to the peptide backbone — which binds reversibly to circulating albumin, extending the drug's time in plasma.

## Is tirzepatide FDA approved?

Tirzepatide is FDA-approved for three indications: type 2 diabetes mellitus (approved May 2022); chronic weight management in adults with obesity or overweight with a weight-related comorbidity (approved November 2023); and moderate-to-severe obstructive sleep apnea in adults with obesity [7, 12, 17]. It is a prescription medicine. It is not approved for type 1 diabetes.

## How long has tirzepatide been around?

Tirzepatide (development code LY3298176) was first described in the published literature in 2018, when Coskun T et al. published the discovery and proof-of-concept paper in Molecular Metabolism [1]. Phase 3 development began around 2019-2020 across the SURPASS (diabetes) and SURMOUNT (obesity) programmes. The FDA first approved it in May 2022 for type 2 diabetes and expanded that approval to chronic weight management in November 2023 [7, 17].

## Is tirzepatide a peptide?

Tirzepatide is a synthetic peptide — specifically, a 39-amino-acid linear peptide engineered from the native GIP hormone sequence, with a fatty-diacid modification added to a lysine side chain [1]. It is in the same broad structural category as other incretin-mimetic drugs (GLP-1 receptor agonists), all of which are peptides or peptide analogs. Its molecular formula is C225H348N48O68; molecular weight 4,813.53 Da.

## Does tirzepatide lower blood pressure?

Yes, blood pressure reductions have been documented in multiple studies as a secondary outcome. A post hoc SURMOUNT-1 cardiometabolic analysis (n=1,605) found systolic blood pressure changed by -14.2 mmHg (95% CI -16.1 to -12.3) in participants who lost at least 35% of body weight, with smaller but consistent reductions at lower weight-loss categories [15]. The blood-pressure improvement appears to track with the degree of weight reduction.

## How does tirzepatide help sleep apnea?

In the SURMOUNT-OSA trial (a phase 3 study in adults with moderate-to-severe obstructive sleep apnea and obesity), tirzepatide reduced the apnea-hypopnea index — the count of breathing interruptions per hour of sleep, the primary grading measure for sleep apnea severity — by approximately 27-30 events per hour more than placebo over the trial period [12]. The mechanism is likely predominantly weight-related: upper-airway anatomy improves as cervical and pharyngeal fat deposits decrease with weight loss, reducing airway obstruction during sleep. This evidence supported the FDA approval of tirzepatide for this indication.

---

An austere editorial record of what the SURMOUNT and SURPASS trials measured — not a clinic, not a prescription, not a vendor.